Novartis Investigative Site

Poole BH15 2JB

0 studies enrolling now · 6 studies all time

What they study most

Chronic Heart Failure With Reduced Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Moderate to Severe Chronic Plaque-Type Psoriasis, Moderate to Severe Plaque-type Psoriasis, Neoplasms, Breast, Relapsing Forms of Multiple Sclerosis

Studies at this site

• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens — Completed